RGPX (Regenerex Pharma) ROA %: -471.54% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerex Pharma ROA %?

Regenerex Pharma RGPX ROA % is -471.54% as of Sep. 2025.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Regenerex Pharma's annualized Net Income for the quarter that ended in Sep. 2025 was $-3.26 Mil. Regenerex Pharma's average Total Assets over the quarter that ended in Sep. 2025 was $0.69 Mil. Therefore, Regenerex Pharma's annualized ROA % for the quarter that ended in Sep. 2025 was -471.54%.

The historical rank and industry rank for Regenerex Pharma's ROA % or its related term are showing as below:

RGPX's ROA % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.74
* Ranked among companies with meaningful ROA % only.

Regenerex Pharma  (OTCPK:RGPX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2025 )
=Net Income/Total Assets
=-3.256/0.6905
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.256 / 0)*(0 / 0.6905)
=Net Margin %*Asset Turnover
=N/A %*0
=-471.54 %

Note: The Net Income data used here is four times the quarterly (Sep. 2025) net income data. The Revenue data used here is four times the quarterly (Sep. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Regenerex Pharma ROA % Related Terms


Regenerex Pharma ROA % Historical Data

* Premium members only.

The historical data trend for Regenerex Pharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerex Pharma ROA % Chart

Regenerex Pharma Annual Data
Trend Nov14 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -263.20 -1,568.00 -1,245.45 -915.76 -248.97

Regenerex Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -311.31 -196.88 -590.58 -262.19 -471.54

RGPX vs CABN, TEKXD, DLYT: ROA % Comparison

For the Medical Instruments & Supplies subindustry, Regenerex Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerex Pharma ROA % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's ROA % distribution charts can be found below:

* The bar in red indicates where Regenerex Pharma's ROA % falls into.



Regenerex Pharma ROA % Calculation

Regenerex Pharma's annualized ROA % for the fiscal year that ended in Mar. 2025 is calculated as:

ROA %=Net Income (A: Mar. 2025 )/( (Total Assets (A: Mar. 2024 )+Total Assets (A: Mar. 2025 ))/ count )
=-2.527/( (0.767+1.263)/ 2 )
=-2.527/1.015
=-248.97 %

Regenerex Pharma's annualized ROA % for the quarter that ended in Sep. 2025 is calculated as:

ROA %=Net Income (Q: Sep. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=-3.256/( (0.763+0.618)/ 2 )
=-3.256/0.6905
=-471.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -471.54% mean?
Regenerex Pharma (RGPX) has a ROA % of -471.54% as of Sep. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Regenerex Pharma and its competitors.
Is Regenerex Pharma's ROA % too high?
Regenerex Pharma's current ROA % is -471.54%.
How does Regenerex Pharma's ROA % compare to CABN and TEKXD?
Regenerex Pharma's ROA % of -471.54% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROA % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.74, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Regenerex Pharma and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerex Pharma's current ROA % is -471.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerex Pharma stock overvalued right now?
Regenerex Pharma (RGPX) has a current ROA % of -471.54%. The current ROA % is -471.54%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Regenerex Pharma (RGPX), the current ROA % is -471.54% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerex Pharma Business Description

Address 5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.